Armata Pharmaceuticals (ARMP) Net Equity Issued and Repurchased (2016 - 2022)
Armata Pharmaceuticals (ARMP) posted Net Equity Issued and Repurchased of -$23000.0 for Q3 2022, up 89.4% sequentially from -$217000.0 in Q2 2022.
Armata Pharmaceuticals (ARMP) Net Equity Issued and Repurchased (2016 - 2022) Analysis & Trends
Armata Pharmaceuticals has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at -$23000.0 in Q3 2022.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$23000.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was $44.4 million (up 68.67% YoY) and the FY2022 annual result came in at $44.4 million, up 68.67% from the prior year.
- Net Equity Issued and Repurchased rose to -$23000.0 in Q3 2022 per ARMP's latest filing, from -$217000.0 in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $44.6 million in Q1 2022 and troughed at -$412000.0 in Q2 2020.
- A 3-year average of $10.4 million and a median of -$23000.0 in 2022 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 128.31% in 2022, down 17.3% in 2022.
- Over 3 years, Net Equity Issued and Repurchased stood at -$26000.0 in 2020, then soared by 26853.85% to $7.0 million in 2021, then tumbled by 100.33% to -$23000.0 in 2022.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered -$23000.0, -$217000.0, and $44.6 million for Q3 2022, Q2 2022, and Q1 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -23,000.00 |
| Sep 30, 2022 | -23,000.00 |
| Jun 30, 2022 | -217,000.00 |
| Jun 30, 2022 | -217,000.00 |
| Mar 31, 2022 | 44.63 Mn |
| Mar 31, 2022 | 44.63 Mn |
| Dec 31, 2021 | 6.96 Mn |
| Dec 31, 2021 | 6.96 Mn |
| Jun 30, 2021 | -185,000.00 |
| Jun 30, 2021 | -185,000.00 |
| Mar 31, 2021 | 19.55 Mn |
| Mar 31, 2021 | 19.55 Mn |
| Sep 30, 2020 | -26,000.00 |
| Sep 30, 2020 | -26,000.00 |
| Jun 30, 2020 | -412,000.00 |
| Jun 30, 2020 | -412,000.00 |
| Mar 31, 2020 | 23.33 Mn |
| Mar 31, 2020 | 23.33 Mn |
| Dec 31, 2016 | 3.34 Mn |
| Dec 31, 2016 | 3.34 Mn |